Cargando…

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

SIMPLE SUMMARY: The current standard of care for patients with HER2-positive early breast cancer who have a pathological complete response after neoadjuvant HER2-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. However, it is not clear how long-ter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swain, Sandra M., Macharia, Harrison, Cortes, Javier, Dang, Chau, Gianni, Luca, Hurvitz, Sara A., Jackisch, Christian, Schneeweiss, Andreas, Slamon, Dennis, Valagussa, Pinuccia, du Toit, Yolande, Heinzmann, Dominik, Knott, Adam, Song, Chunyan, Cortazar, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599862/ https://www.ncbi.nlm.nih.gov/pubmed/36291835 http://dx.doi.org/10.3390/cancers14205051

Ejemplares similares

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Update on HER2-directed therapy
por: Slamon, D
Publicado: (2005)

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records
por: Polito, Letizia, et al.
Publicado: (2023)

Clinical evaluation of BCL-2/X(L) levels pre- and post- HER2-targeted therapy
por: Zoeller, Jason J., et al.
Publicado: (2021)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer
por: Korner, Eli J., et al.
Publicado: (2015)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer
por: Perez, Edith A, et al.
Publicado: (2014)

Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom: Konsequenzen für die histopathologische Diagnostik
por: Denkert, Carsten, et al.
Publicado: (2022)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
por: Kaufman, Peter A, et al.
Publicado: (2014)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
por: Retsky, Michael, et al.
Publicado: (2004)

Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour
por: Demicheli, Romano, et al.
Publicado: (2004)

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial
por: Triulzi, Tiziana, et al.
Publicado: (2021)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity
por: Huang, Yao, et al.
Publicado: (2016)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
por: Lin, Nancy U., et al.
Publicado: (2022)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t63em8u7vpg6oqralth46nsjkh